 Scott Sagel
Concepts (404)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 101 | 2025 | 1114 | 12.320 |
Why?
| | Aminophenols | 21 | 2025 | 156 | 4.080 |
Why?
| | Kartagener Syndrome | 24 | 2025 | 30 | 3.570 |
Why?
| | Ciliary Motility Disorders | 16 | 2025 | 24 | 3.480 |
Why?
| | Quinolones | 19 | 2025 | 137 | 3.280 |
Why?
| | Sputum | 26 | 2025 | 311 | 2.880 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 28 | 2025 | 329 | 2.840 |
Why?
| | Benzodioxoles | 12 | 2025 | 115 | 2.080 |
Why?
| | Lung | 26 | 2025 | 4060 | 1.800 |
Why?
| | Inflammation | 16 | 2023 | 2837 | 1.670 |
Why?
| | Respiratory Function Tests | 21 | 2024 | 600 | 1.590 |
Why?
| | Respiratory System Agents | 3 | 2022 | 22 | 1.500 |
Why?
| | Bronchiectasis | 4 | 2025 | 111 | 1.450 |
Why?
| | Pseudomonas Infections | 11 | 2025 | 225 | 1.360 |
Why?
| | Aminopyridines | 6 | 2022 | 98 | 1.340 |
Why?
| | Biomarkers | 25 | 2022 | 4149 | 1.340 |
Why?
| | Genetic Testing | 7 | 2021 | 460 | 1.330 |
Why?
| | Neonatal Screening | 5 | 2021 | 169 | 1.330 |
Why?
| | Cilia | 17 | 2025 | 178 | 1.310 |
Why?
| | Chloride Channel Agonists | 13 | 2025 | 84 | 1.280 |
Why?
| | Lung Diseases | 6 | 2023 | 767 | 1.270 |
Why?
| | Mycobacterium avium-intracellulare Infection | 3 | 2021 | 62 | 1.240 |
Why?
| | Anti-Bacterial Agents | 15 | 2024 | 1809 | 1.200 |
Why?
| | Child | 78 | 2025 | 21935 | 1.170 |
Why?
| | Azithromycin | 6 | 2024 | 100 | 1.130 |
Why?
| | Forced Expiratory Volume | 17 | 2025 | 531 | 1.090 |
Why?
| | Anti-Inflammatory Agents | 4 | 2020 | 496 | 1.060 |
Why?
| | Adolescent | 71 | 2025 | 21513 | 1.040 |
Why?
| | Mutation | 29 | 2022 | 3958 | 1.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 7 | 2019 | 652 | 1.020 |
Why?
| | Trypsinogen | 3 | 2021 | 11 | 1.010 |
Why?
| | Disease Progression | 19 | 2025 | 2757 | 0.880 |
Why?
| | Vitamins | 2 | 2018 | 185 | 0.840 |
Why?
| | Humans | 135 | 2025 | 137585 | 0.800 |
Why?
| | Young Adult | 43 | 2025 | 13209 | 0.800 |
Why?
| | Indoles | 5 | 2025 | 412 | 0.780 |
Why?
| | Female | 93 | 2025 | 73304 | 0.780 |
Why?
| | Male | 90 | 2025 | 67762 | 0.780 |
Why?
| | Pyrazoles | 5 | 2025 | 423 | 0.770 |
Why?
| | Antioxidants | 3 | 2018 | 584 | 0.760 |
Why?
| | Pseudomonas aeruginosa | 11 | 2023 | 352 | 0.750 |
Why?
| | Ethambutol | 1 | 2021 | 26 | 0.720 |
Why?
| | Algorithms | 4 | 2021 | 1704 | 0.710 |
Why?
| | Rifampin | 1 | 2021 | 84 | 0.690 |
Why?
| | Breath Tests | 5 | 2022 | 87 | 0.640 |
Why?
| | Child, Preschool | 33 | 2025 | 11074 | 0.640 |
Why?
| | Mycobacterium avium Complex | 3 | 2021 | 88 | 0.620 |
Why?
| | Dyneins | 7 | 2024 | 33 | 0.590 |
Why?
| | Prospective Studies | 29 | 2025 | 7604 | 0.580 |
Why?
| | Longitudinal Studies | 14 | 2025 | 2844 | 0.580 |
Why?
| | Pyridines | 4 | 2025 | 506 | 0.580 |
Why?
| | Drug Combinations | 9 | 2025 | 343 | 0.570 |
Why?
| | Dietary Supplements | 3 | 2018 | 561 | 0.540 |
Why?
| | Malnutrition | 1 | 2018 | 83 | 0.540 |
Why?
| | C-Reactive Protein | 8 | 2022 | 410 | 0.540 |
Why?
| | Nontuberculous Mycobacteria | 3 | 2023 | 205 | 0.530 |
Why?
| | Leukocyte Elastase | 7 | 2023 | 76 | 0.520 |
Why?
| | Hospitalization | 3 | 2025 | 2199 | 0.510 |
Why?
| | Drug Discovery | 1 | 2016 | 142 | 0.480 |
Why?
| | Leukocyte L1 Antigen Complex | 5 | 2022 | 32 | 0.470 |
Why?
| | Specimen Handling | 3 | 2025 | 183 | 0.470 |
Why?
| | Infant | 23 | 2025 | 9465 | 0.460 |
Why?
| | Infant, Newborn | 16 | 2025 | 6079 | 0.450 |
Why?
| | Mycobacterium Infections, Nontuberculous | 4 | 2023 | 363 | 0.450 |
Why?
| | Adult | 44 | 2025 | 37929 | 0.440 |
Why?
| | Metabolomics | 1 | 2019 | 678 | 0.440 |
Why?
| | Sweat | 5 | 2025 | 47 | 0.430 |
Why?
| | Nitric Oxide | 5 | 2019 | 915 | 0.430 |
Why?
| | Retrospective Studies | 21 | 2025 | 15657 | 0.430 |
Why?
| | Automation | 1 | 2014 | 95 | 0.420 |
Why?
| | Granulocyte Colony-Stimulating Factor | 4 | 2022 | 74 | 0.420 |
Why?
| | United States | 21 | 2025 | 14841 | 0.420 |
Why?
| | Exocrine Pancreatic Insufficiency | 2 | 2010 | 21 | 0.410 |
Why?
| | Respiratory Tract Infections | 6 | 2025 | 390 | 0.400 |
Why?
| | Clinical Trials as Topic | 5 | 2015 | 1050 | 0.390 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2014 | 141 | 0.390 |
Why?
| | Blood Glucose | 5 | 2025 | 2186 | 0.390 |
Why?
| | Respiratory System | 4 | 2019 | 157 | 0.380 |
Why?
| | Microbiota | 5 | 2023 | 762 | 0.370 |
Why?
| | Tomography, X-Ray Computed | 7 | 2025 | 2691 | 0.370 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 2011 | 16 | 0.360 |
Why?
| | Vitamin K Deficiency | 1 | 2010 | 9 | 0.350 |
Why?
| | Sensitivity and Specificity | 7 | 2021 | 1946 | 0.350 |
Why?
| | Cohort Studies | 14 | 2025 | 5742 | 0.340 |
Why?
| | Vitamin A Deficiency | 1 | 2010 | 26 | 0.340 |
Why?
| | Staphylococcal Infections | 3 | 2019 | 400 | 0.340 |
Why?
| | Cytokines | 6 | 2023 | 2085 | 0.340 |
Why?
| | Pyrrolidines | 3 | 2025 | 79 | 0.330 |
Why?
| | Quality of Life | 5 | 2024 | 2892 | 0.330 |
Why?
| | Severity of Illness Index | 10 | 2024 | 2828 | 0.330 |
Why?
| | Otitis Media with Effusion | 2 | 2025 | 20 | 0.320 |
Why?
| | Bronchoscopy | 2 | 2008 | 223 | 0.320 |
Why?
| | Secretory Leukocyte Peptidase Inhibitor | 1 | 2009 | 6 | 0.310 |
Why?
| | Treatment Outcome | 15 | 2025 | 10811 | 0.310 |
Why?
| | Lactoferrin | 1 | 2009 | 31 | 0.310 |
Why?
| | Bronchitis | 1 | 2009 | 44 | 0.300 |
Why?
| | Muramidase | 1 | 2009 | 78 | 0.300 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 186 | 0.290 |
Why?
| | Proteomics | 3 | 2022 | 1111 | 0.290 |
Why?
| | Tomography | 2 | 2018 | 40 | 0.290 |
Why?
| | Diverticulum | 1 | 2007 | 12 | 0.280 |
Why?
| | Tracheal Diseases | 1 | 2007 | 15 | 0.280 |
Why?
| | Administration, Oral | 3 | 2018 | 816 | 0.270 |
Why?
| | Tracheoesophageal Fistula | 1 | 2007 | 33 | 0.270 |
Why?
| | Data Interpretation, Statistical | 2 | 2021 | 363 | 0.260 |
Why?
| | Genotype | 10 | 2025 | 1916 | 0.260 |
Why?
| | Digestive System Surgical Procedures | 1 | 2007 | 106 | 0.260 |
Why?
| | Heterotaxy Syndrome | 2 | 2023 | 14 | 0.260 |
Why?
| | Reproductive Health | 2 | 2017 | 90 | 0.260 |
Why?
| | Phenotype | 8 | 2025 | 3196 | 0.250 |
Why?
| | Respiratory Distress Syndrome, Newborn | 2 | 2025 | 106 | 0.250 |
Why?
| | Proteins | 4 | 2024 | 1009 | 0.240 |
Why?
| | Pulmonary Atelectasis | 1 | 2025 | 15 | 0.240 |
Why?
| | Bacteria | 5 | 2023 | 858 | 0.240 |
Why?
| | Leukocyte Count | 5 | 2012 | 329 | 0.240 |
Why?
| | Middle Ear Ventilation | 1 | 2025 | 15 | 0.230 |
Why?
| | Meconium Ileus | 1 | 2024 | 5 | 0.230 |
Why?
| | Hearing Loss, Conductive | 1 | 2025 | 25 | 0.230 |
Why?
| | Interleukin-8 | 7 | 2012 | 268 | 0.230 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2005 | 132 | 0.220 |
Why?
| | Age Factors | 5 | 2020 | 3295 | 0.220 |
Why?
| | Chlorides | 3 | 2022 | 136 | 0.220 |
Why?
| | Rhinitis | 2 | 2019 | 158 | 0.220 |
Why?
| | Probability | 3 | 2016 | 304 | 0.220 |
Why?
| | Glucose Tolerance Test | 5 | 2025 | 366 | 0.220 |
Why?
| | Situs Inversus | 1 | 2023 | 3 | 0.220 |
Why?
| | DNA, Bacterial | 4 | 2017 | 337 | 0.220 |
Why?
| | Oropharynx | 3 | 2015 | 46 | 0.210 |
Why?
| | Cytoskeletal Proteins | 4 | 2024 | 158 | 0.210 |
Why?
| | Models, Neurological | 1 | 2006 | 242 | 0.210 |
Why?
| | Axonemal Dyneins | 4 | 2025 | 9 | 0.210 |
Why?
| | Sinusitis | 2 | 2019 | 221 | 0.210 |
Why?
| | Diabetes Mellitus | 2 | 2025 | 1040 | 0.210 |
Why?
| | Follow-Up Studies | 7 | 2018 | 5131 | 0.200 |
Why?
| | Mucociliary Clearance | 2 | 2021 | 45 | 0.200 |
Why?
| | Neuronal Plasticity | 1 | 2006 | 290 | 0.200 |
Why?
| | Fetal Diseases | 1 | 2024 | 173 | 0.200 |
Why?
| | Metagenome | 3 | 2013 | 147 | 0.200 |
Why?
| | Monitoring, Immunologic | 1 | 2002 | 25 | 0.190 |
Why?
| | Respiration Disorders | 1 | 2023 | 77 | 0.190 |
Why?
| | Genetic Markers | 4 | 2016 | 344 | 0.190 |
Why?
| | Uteroglobin | 1 | 2022 | 23 | 0.190 |
Why?
| | Calreticulin | 1 | 2022 | 28 | 0.190 |
Why?
| | HMGB Proteins | 1 | 2022 | 18 | 0.190 |
Why?
| | Chemistry, Clinical | 1 | 2002 | 12 | 0.190 |
Why?
| | Serum Amyloid A Protein | 2 | 2019 | 33 | 0.190 |
Why?
| | Peptide Hydrolases | 1 | 2023 | 111 | 0.190 |
Why?
| | Hydrogen | 1 | 2022 | 70 | 0.190 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2021 | 11 | 0.190 |
Why?
| | Synapses | 1 | 2006 | 427 | 0.190 |
Why?
| | Prognosis | 5 | 2018 | 4030 | 0.180 |
Why?
| | Body Mass Index | 5 | 2020 | 2389 | 0.180 |
Why?
| | Antibiotics, Antitubercular | 1 | 2021 | 37 | 0.180 |
Why?
| | Desmosine | 2 | 2012 | 6 | 0.180 |
Why?
| | Cross-Sectional Studies | 8 | 2024 | 5472 | 0.180 |
Why?
| | DNA Mutational Analysis | 5 | 2014 | 399 | 0.170 |
Why?
| | Rhodospirillaceae | 1 | 2020 | 4 | 0.170 |
Why?
| | Disease Management | 3 | 2015 | 628 | 0.170 |
Why?
| | Leptin | 1 | 2022 | 236 | 0.170 |
Why?
| | Cross-Over Studies | 2 | 2021 | 564 | 0.170 |
Why?
| | Glucose | 2 | 2023 | 1020 | 0.170 |
Why?
| | Mycobacterium abscessus | 1 | 2021 | 117 | 0.160 |
Why?
| | Quinolines | 3 | 2025 | 178 | 0.160 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 319 | 0.160 |
Why?
| | Patient Acuity | 1 | 2019 | 47 | 0.160 |
Why?
| | Sleep Apnea, Central | 1 | 1999 | 10 | 0.160 |
Why?
| | Antitubercular Agents | 1 | 2021 | 206 | 0.160 |
Why?
| | Proteome | 2 | 2022 | 472 | 0.150 |
Why?
| | Alleles | 4 | 2017 | 891 | 0.150 |
Why?
| | Autonomic Nervous System Diseases | 1 | 1999 | 36 | 0.150 |
Why?
| | Machine Learning | 1 | 2024 | 493 | 0.150 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2018 | 752 | 0.150 |
Why?
| | Prevalence | 3 | 2025 | 2734 | 0.150 |
Why?
| | Pneumonia | 2 | 2017 | 639 | 0.150 |
Why?
| | Predictive Value of Tests | 4 | 2023 | 2031 | 0.150 |
Why?
| | Respiratory Tract Diseases | 1 | 2020 | 184 | 0.150 |
Why?
| | Hypoglycemia | 1 | 2023 | 445 | 0.150 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2018 | 21 | 0.150 |
Why?
| | Case-Control Studies | 6 | 2020 | 3556 | 0.150 |
Why?
| | Air | 1 | 2018 | 37 | 0.150 |
Why?
| | Nutritional Status | 2 | 2018 | 350 | 0.140 |
Why?
| | Oxidative Stress | 2 | 2018 | 1317 | 0.140 |
Why?
| | Saliva | 2 | 2015 | 242 | 0.140 |
Why?
| | Hirschsprung Disease | 1 | 1999 | 88 | 0.140 |
Why?
| | Aptamers, Nucleotide | 1 | 2019 | 83 | 0.140 |
Why?
| | Reproductive Health Services | 1 | 2017 | 19 | 0.140 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2023 | 1242 | 0.140 |
Why?
| | Double-Blind Method | 3 | 2018 | 1993 | 0.140 |
Why?
| | Health Services Misuse | 1 | 2017 | 33 | 0.140 |
Why?
| | Respiration | 1 | 2018 | 199 | 0.140 |
Why?
| | Lipids | 1 | 2022 | 672 | 0.140 |
Why?
| | Neutrophils | 3 | 2015 | 1238 | 0.140 |
Why?
| | Insulin | 2 | 2025 | 2409 | 0.140 |
Why?
| | Tobramycin | 2 | 2023 | 52 | 0.140 |
Why?
| | Clofazimine | 1 | 2017 | 15 | 0.140 |
Why?
| | Coinfection | 2 | 2020 | 137 | 0.130 |
Why?
| | Middle Aged | 16 | 2025 | 33479 | 0.130 |
Why?
| | Body Height | 1 | 2017 | 199 | 0.130 |
Why?
| | Neurons | 1 | 2006 | 1590 | 0.130 |
Why?
| | Axoneme | 2 | 2013 | 9 | 0.130 |
Why?
| | Immunologic Tests | 1 | 2016 | 16 | 0.130 |
Why?
| | Sexual Health | 1 | 2017 | 59 | 0.130 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 234 | 0.120 |
Why?
| | Body Weight | 1 | 2020 | 985 | 0.120 |
Why?
| | Postoperative Complications | 1 | 2007 | 2654 | 0.120 |
Why?
| | Dried Blood Spot Testing | 1 | 2016 | 104 | 0.120 |
Why?
| | Exome | 5 | 2014 | 231 | 0.120 |
Why?
| | Spirometry | 4 | 2015 | 281 | 0.120 |
Why?
| | Time Factors | 4 | 2018 | 6828 | 0.120 |
Why?
| | Diagnostic Tests, Routine | 1 | 2016 | 110 | 0.120 |
Why?
| | Targeted Gene Repair | 1 | 2015 | 1 | 0.120 |
Why?
| | Patient Selection | 1 | 2019 | 696 | 0.120 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 411 | 0.120 |
Why?
| | Pedigree | 5 | 2013 | 514 | 0.110 |
Why?
| | Microtubule-Associated Proteins | 2 | 2013 | 196 | 0.110 |
Why?
| | Zebrafish | 3 | 2013 | 499 | 0.110 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1774 | 0.110 |
Why?
| | Insulin Resistance | 1 | 2023 | 1208 | 0.110 |
Why?
| | Bacteria, Anaerobic | 2 | 2011 | 25 | 0.110 |
Why?
| | Hyperglycemia | 1 | 2018 | 347 | 0.110 |
Why?
| | Nasal Mucosa | 4 | 2019 | 107 | 0.110 |
Why?
| | Microscopy, Electron, Transmission | 4 | 2016 | 156 | 0.110 |
Why?
| | Ubiquinone | 2 | 2010 | 29 | 0.100 |
Why?
| | Survival Rate | 2 | 2018 | 1972 | 0.100 |
Why?
| | Homozygote | 3 | 2020 | 203 | 0.100 |
Why?
| | Antigens, Surface | 1 | 2013 | 154 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 316 | 0.100 |
Why?
| | Intestine, Small | 1 | 2014 | 156 | 0.100 |
Why?
| | Sexual Behavior | 1 | 2017 | 485 | 0.100 |
Why?
| | Vital Capacity | 1 | 2014 | 311 | 0.100 |
Why?
| | GTP-Binding Proteins | 1 | 2013 | 161 | 0.100 |
Why?
| | Neutrophil Activation | 1 | 2013 | 80 | 0.100 |
Why?
| | Linear Models | 3 | 2024 | 849 | 0.100 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 63 | 0.100 |
Why?
| | Precision Medicine | 1 | 2016 | 429 | 0.090 |
Why?
| | Elastin | 1 | 2012 | 78 | 0.090 |
Why?
| | DNA | 2 | 2018 | 1459 | 0.090 |
Why?
| | Proteolysis | 1 | 2012 | 177 | 0.090 |
Why?
| | Glycoproteins | 1 | 2013 | 342 | 0.090 |
Why?
| | Mycobacterium | 1 | 2013 | 108 | 0.090 |
Why?
| | Models, Statistical | 1 | 2016 | 669 | 0.090 |
Why?
| | Nasal Cavity | 1 | 2011 | 52 | 0.090 |
Why?
| | Turbinates | 1 | 2011 | 14 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 327 | 0.090 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1062 | 0.090 |
Why?
| | Biomarkers, Pharmacological | 1 | 2010 | 28 | 0.090 |
Why?
| | Dinoprost | 1 | 2010 | 44 | 0.090 |
Why?
| | Inflammation Mediators | 2 | 2005 | 513 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 1 | 2013 | 558 | 0.080 |
Why?
| | Biopsy | 4 | 2015 | 1129 | 0.080 |
Why?
| | Metagenomics | 2 | 2021 | 169 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1587 | 0.080 |
Why?
| | Interprofessional Relations | 1 | 2012 | 283 | 0.080 |
Why?
| | Microbial Sensitivity Tests | 2 | 2021 | 361 | 0.080 |
Why?
| | Membrane Potentials | 2 | 2010 | 284 | 0.080 |
Why?
| | Morbidity | 2 | 2018 | 324 | 0.080 |
Why?
| | Chronic Disease | 2 | 2015 | 1793 | 0.080 |
Why?
| | Canada | 2 | 2024 | 418 | 0.080 |
Why?
| | Lung Injury | 1 | 2012 | 219 | 0.080 |
Why?
| | Pseudomonas | 2 | 2022 | 31 | 0.080 |
Why?
| | Exotoxins | 1 | 2008 | 16 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2531 | 0.070 |
Why?
| | Confidence Intervals | 1 | 2009 | 329 | 0.070 |
Why?
| | Heterozygote | 1 | 2009 | 293 | 0.070 |
Why?
| | Administration, Inhalation | 2 | 2023 | 688 | 0.070 |
Why?
| | Electric Impedance | 2 | 2018 | 107 | 0.070 |
Why?
| | Peroxidase | 2 | 2022 | 175 | 0.070 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2007 | 40 | 0.070 |
Why?
| | Pregnancy Rate | 2 | 2017 | 65 | 0.070 |
Why?
| | RNA Precursors | 1 | 2008 | 154 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 740 | 0.070 |
Why?
| | Pregnancy | 4 | 2024 | 6763 | 0.070 |
Why?
| | Sequence Analysis, DNA | 3 | 2015 | 812 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1502 | 0.060 |
Why?
| | Diagnostic Errors | 1 | 2007 | 170 | 0.060 |
Why?
| | Genomics | 2 | 2021 | 795 | 0.060 |
Why?
| | Biomedical Research | 1 | 2012 | 692 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 2426 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2010 | 3284 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2013 | 2833 | 0.060 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2005 | 26 | 0.060 |
Why?
| | Audiometry, Pure-Tone | 1 | 2025 | 30 | 0.060 |
Why?
| | Tympanic Membrane Perforation | 1 | 2025 | 17 | 0.060 |
Why?
| | Needs Assessment | 2 | 2017 | 376 | 0.060 |
Why?
| | Incidence | 2 | 2025 | 2804 | 0.060 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 16 | 0.060 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 95 | 0.060 |
Why?
| | Cephalosporins | 1 | 2024 | 48 | 0.060 |
Why?
| | Colorado | 2 | 2018 | 4565 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2008 | 450 | 0.050 |
Why?
| | Reference Values | 2 | 2017 | 816 | 0.050 |
Why?
| | Vasodilator Agents | 1 | 2006 | 331 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2006 | 279 | 0.050 |
Why?
| | Microscopy, Electron | 2 | 2015 | 443 | 0.050 |
Why?
| | Diabetic Retinopathy | 1 | 2006 | 189 | 0.050 |
Why?
| | Piperazines | 1 | 2006 | 350 | 0.050 |
Why?
| | Registries | 2 | 2025 | 2035 | 0.050 |
Why?
| | Symptom Assessment | 1 | 2024 | 128 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2009 | 828 | 0.050 |
Why?
| | Pancreatic Elastase | 1 | 2022 | 58 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2024 | 499 | 0.050 |
Why?
| | Risk Factors | 3 | 2025 | 10388 | 0.050 |
Why?
| | Glucagon | 1 | 2023 | 109 | 0.050 |
Why?
| | Cell Count | 1 | 2002 | 324 | 0.050 |
Why?
| | Aspergillus fumigatus | 1 | 2021 | 26 | 0.050 |
Why?
| | Constipation | 1 | 2022 | 94 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2025 | 956 | 0.040 |
Why?
| | Nucleotides | 1 | 2022 | 125 | 0.040 |
Why?
| | Computer Simulation | 1 | 2006 | 978 | 0.040 |
Why?
| | Down Syndrome | 1 | 2007 | 496 | 0.040 |
Why?
| | Cough | 1 | 2001 | 122 | 0.040 |
Why?
| | Symptom Flare Up | 1 | 2020 | 39 | 0.040 |
Why?
| | Mutant Proteins | 1 | 2020 | 103 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 117 | 0.040 |
Why?
| | Recovery of Function | 1 | 2024 | 653 | 0.040 |
Why?
| | Prediabetic State | 1 | 2023 | 253 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2017 | 1329 | 0.040 |
Why?
| | Asthma | 2 | 2013 | 2295 | 0.040 |
Why?
| | British Columbia | 1 | 2018 | 21 | 0.040 |
Why?
| | Fatal Outcome | 1 | 1999 | 303 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 976 | 0.040 |
Why?
| | Pilot Projects | 2 | 2017 | 1710 | 0.040 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2023 | 641 | 0.030 |
Why?
| | Early Medical Intervention | 1 | 2018 | 57 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 691 | 0.030 |
Why?
| | Ultrasonography, Prenatal | 1 | 1999 | 285 | 0.030 |
Why?
| | Age Distribution | 1 | 2017 | 392 | 0.030 |
Why?
| | Length of Stay | 1 | 2022 | 1215 | 0.030 |
Why?
| | Ontario | 1 | 2016 | 148 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2017 | 167 | 0.030 |
Why?
| | Microscopy, Video | 1 | 2015 | 25 | 0.030 |
Why?
| | Respiratory Therapy | 1 | 2015 | 23 | 0.030 |
Why?
| | Radiography | 1 | 2017 | 822 | 0.030 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2015 | 36 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 1024 | 0.030 |
Why?
| | Enterobacteriaceae | 1 | 2015 | 40 | 0.030 |
Why?
| | Staphylococcus | 1 | 2015 | 76 | 0.030 |
Why?
| | Enterobacteriaceae Infections | 1 | 2015 | 43 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2017 | 5778 | 0.030 |
Why?
| | North America | 1 | 2015 | 313 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2006 | 1910 | 0.030 |
Why?
| | Pneumococcal Vaccines | 1 | 2015 | 142 | 0.030 |
Why?
| | Genetic Therapy | 1 | 2016 | 297 | 0.030 |
Why?
| | Counseling | 1 | 2017 | 391 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2014 | 75 | 0.030 |
Why?
| | Sex Factors | 1 | 2020 | 2071 | 0.030 |
Why?
| | Planarians | 1 | 2013 | 1 | 0.030 |
Why?
| | Chlamydomonas | 1 | 2013 | 3 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 820 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1509 | 0.030 |
Why?
| | Xenopus laevis | 1 | 2013 | 106 | 0.030 |
Why?
| | Open Reading Frames | 1 | 2013 | 123 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2014 | 560 | 0.020 |
Why?
| | Cytoplasm | 1 | 2013 | 274 | 0.020 |
Why?
| | Genes, Recessive | 1 | 2012 | 78 | 0.020 |
Why?
| | Computer Communication Networks | 1 | 2012 | 33 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2057 | 0.020 |
Why?
| | Placebos | 1 | 2012 | 199 | 0.020 |
Why?
| | Superoxides | 1 | 2013 | 202 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 346 | 0.020 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2012 | 139 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2014 | 377 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 390 | 0.020 |
Why?
| | Airway Remodeling | 1 | 2012 | 64 | 0.020 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2011 | 22 | 0.020 |
Why?
| | Biota | 1 | 2011 | 34 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2012 | 404 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2074 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2013 | 861 | 0.020 |
Why?
| | Influenza Vaccines | 1 | 2015 | 539 | 0.020 |
Why?
| | Autoantigens | 1 | 2013 | 430 | 0.020 |
Why?
| | Biofilms | 1 | 2013 | 260 | 0.020 |
Why?
| | Ion Channels | 1 | 2010 | 133 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2013 | 539 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 617 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 660 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2012 | 778 | 0.020 |
Why?
| | Genes, rRNA | 1 | 2007 | 41 | 0.020 |
Why?
| | gamma-Tocopherol | 1 | 2007 | 7 | 0.020 |
Why?
| | Mexico | 1 | 2008 | 225 | 0.020 |
Why?
| | beta Carotene | 1 | 2007 | 21 | 0.020 |
Why?
| | Genes, Bacterial | 1 | 2007 | 164 | 0.020 |
Why?
| | Micelles | 1 | 2007 | 39 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2013 | 1096 | 0.020 |
Why?
| | Biological Availability | 1 | 2007 | 148 | 0.020 |
Why?
| | Protein Binding | 1 | 2013 | 2224 | 0.020 |
Why?
| | Animals | 3 | 2013 | 36940 | 0.020 |
Why?
| | Leukocytes | 1 | 2008 | 311 | 0.020 |
Why?
| | ROC Curve | 1 | 2008 | 554 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 767 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2006 | 58 | 0.020 |
Why?
| | Research Design | 1 | 2012 | 1139 | 0.020 |
Why?
| | Aged | 2 | 2017 | 23961 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 1040 | 0.010 |
Why?
| | Sulfones | 1 | 2006 | 110 | 0.010 |
Why?
| | Acute Disease | 1 | 2008 | 1007 | 0.010 |
Why?
| | Genetic Carrier Screening | 1 | 2004 | 28 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7635 | 0.010 |
Why?
| | Purines | 1 | 2006 | 176 | 0.010 |
Why?
| | Infant Care | 1 | 2004 | 45 | 0.010 |
Why?
| | Rats | 1 | 2013 | 5647 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2607 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2900 | 0.010 |
Why?
| | Infant Nutritional Physiological Phenomena | 1 | 2004 | 146 | 0.010 |
Why?
|
|
Sagel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|